A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient’s large, stage 4 tumor was reduced in size by 70%.
After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis.
NeoPlas Innovation’s combination of FDA-approved drugs appears to improve those odds for some patients, based on this result and similar ones seen before the protocol’s public availability.
The tumor reduction correlated with resolution of the patient’s symptoms of pain and digestive problems. “The cancer isn’t gone,” emphasized NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell.
“There are still several metastatic lesions to address, but this kind of response is virtually unheard of in pancreatic cancer. At the very least, we’re looking at his having many, many months of added survival with a quality of life he can truly enjoy.”
The cholesterol drug Lovastatin is a key part of this treatment that has arrested or eradicated tumors in 78% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today.
Read more at Forbes
